Certified by Founder Lodge
Longwood Fund
United States - Boston, MA
INVESTOR
1 Disclosed Funding Rounds $65,333,745
11 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.
| Company | Date | Round | Raised |
|---|---|---|---|
Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
Be Biopharma |
October, 23 ,2024 | Unknown | $82,000,000 |
AAVantgarde Bio |
June, 07 ,2023 | Series A | $65,333,745 |
Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
Tome Biosciences |
December, 14 ,2023 | Series B | $213,000,000 |
Engrail Therapeutics |
March, 20 ,2024 | Series B | $157,000,000 |
Be Biopharma |
October, 23 ,2024 | Unknown | $82,000,000 |
Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
Avenzo Therapeutics |
September, 23 ,2025 | Series B | $60,000,000 |
Crystalys Therapeutics |
October, 01 ,2025 | Series A | $205,000,000 |
Newleos Therapeutics
Be Biopharma
AAVantgarde Bio
Solu Therapeutics
Sitryx
Tome Biosciences
Engrail Therapeutics
Avenzo Therapeutics
Crystalys Therapeutics
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Mantis Space | $10,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)